Replies to post #240052 on Biotech Values

[DewDiligence]

PFE—Prevnar-20 hits_primary_endpoints_in phase-3 trial_in infants:

https://www.businesswire.com/news/home/20220812005073/en

The Prevnar franchise is PFE’s biggest seller not related to COVID. In the adult segment of the market, Prevnar-20 has achieved a 97% market share with MRK’s Vaxneuvance a very distant #2 (#msg-169520866, #msg-166441188).

The pediatric segment of the pneumococcal-vaccine market figures to be more competitive since MRK’s Vaxneuvance has a head start from its FDA approval in Jun 2022 (#msg-169208458).

[DewDiligence]

ACIP recommends Prevar-20 for_adults_who_previously_got Prevnar-13:

https://www.pfizer.com/news/announcements/advisory-committee-immunization-practices-recommends-pfizers-prevnar-20r-adults

This is a pretty big deal for PFE insofar as it makes Prevnar-20 a source of incremental Prevnar-franchise revenue rather than merely a replacement for Prevar-13 sales.

See #msg-164292101, #msg-166441188, #msg-169520866 and #msg-166441188 for related info.